Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MWnDfZRwfG:6aXPpeJkh[XO|YYm= NXjQSoJIPzJiaB?= NHPjUGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1zMjDuUS=> MkHkNVk3PTR2MEi=
RS4-11 cells M3f2WmZ2dmO2aX;uJIF{e2G7 Ml;pNkBp NUXYeI0yUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDSV|QuOTFiY3XscJMh[W[2ZYKgNkBpenNiYomg[Yxm[3S{b3Po[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwQVE{KG6P NXPGPHBHOTl4NUS0NFg>
CGTH-W-1 cell M1u3UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFIvPjVizszN M3viR3NCVkeHUh?=
SW982 cell NH7me49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXpTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlU5KM7:TR?= M4fGTHNCVkeHUh?=
human EoL-1-cell cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYntPJRFUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFghdk1? MUHTRW5ITVJ?
MOLM-13 cells MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlT6O|IhcA>? M1HSXGlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaHX0[ZJwgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNU2xONTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlA2PSEQvF2= MlPINlYxQDFyMkO=
KASUMI-1 cell M{TC[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGtCW1WPST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xPjBzNjFOwG0> NEDJc4tUSU6JRWK=
NCI-H1755 cell MkjGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEXXe2dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[yO|Mh|ryP NWC3emVVW0GQR1XS
human MES-SA cell MmG3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG1GWy2VQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFc2PDRizszN NELMcFZUSU6JRWK=
human HCC1395 cell M4XleWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXT[m1KdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6NEK4JO69VQ>? M2C2T3NCVkeHUh?=
human D-336MG cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> MmfaV2FPT0WU
CHP-212 cell M{DUfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{HtSmlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5N{Og{txO MWDTRW5ITVJ?
human KM12 cell NIPXUnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzBTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVI4PSEQvF2= MXrTRW5ITVJ?
A204 cell NFnibFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoS0TY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFA2OiEQvF2= M4r4fnNCVkeHUh?=
CAL-51 cell NWTBco15T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVrOUop2UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyN{C5JO69VQ>? MlrUV2FPT0WU
human A431 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1nsTmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzOTZizszN NGX3b2pUSU6JRWK=
NCI-H650 cell MkPxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTdyODFOwG0> NULv[HpzW0GQR1XS
A427 cell NWTKR|hIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxPVE5KM7:TR?= MoPZV2FPT0WU
human 769-P cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlA5OiEQvF2= NGiwSlRUSU6JRWK=
SW1710 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLEOXVKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTN|MU[g{txO MV;TRW5ITVJ?
human H4 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{m2N{DPxE1? NEPMPIZUSU6JRWK=
HT-1080 cell NWW5WpZoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rIZWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEKg{txO MX\TRW5ITVJ?
human PANC-03-27 cell NED6SZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLMUYR4UW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlAzKM7:TR?= M4HNZXNCVkeHUh?=
A375 cells NGjn[2hEgXSxdH;4bYNqfHliYYPzZZk> NEnINHo4OiCq M1Tre3RwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBKSzVyPUCuNVgh|ryP NEDndmcyQTZ3NESwPC=>
human HOP-62 cell Mm\5SpVv[3Srb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVgxPzNizszN NWL1dllYW0GQR1XS
human U031 cell MlXZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3ld2tKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6Pjl6IN88US=> MVnTRW5ITVJ?
mouse BAF3 cells NWTFdoJ6WHKxbHnm[ZJifGmxbjDhd5NigQ>? MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1? NHrsXYkzOTl|NkW0Ni=>
human G-402 cell NFjpeWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFI2OyEQvF2= MX3TRW5ITVJ?
human G-361 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnHXTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlA5PTNizszN MnvIV2FPT0WU
NCI-H810 cell NULlfWw5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;sXmRsUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkGwNlch|ryP M2CwOHNCVkeHUh?=
NCI-H2030 cell M{fhV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUj4O4o{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzNFA3KM7:TR?= MYLTRW5ITVJ?
human HCT-116 cell NGjpdpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHzE[3NKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|NU[4JO69VQ>? MV7TRW5ITVJ?
human SNU-423 cell NVfFUZo3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmWyTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0> M1\i[XNCVkeHUh?=
human SCC-4 cell NIO3dHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGH0OGFKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzl4NzFOwG0> MXrTRW5ITVJ?
human SW48 cell NUi3cmxnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIfIdoxKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI3PjhizszN NEnzNJpUSU6JRWK=
human SF295 cell M{[5W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;FT|JKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzJ3NzFOwG0> NIC1[WdUSU6JRWK=
MDA-MB-231 cell NG\nXHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? MkjIV2FPT0WU
A172 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkDyTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPVE2KM7:TR?= MkPXV2FPT0WU
human BCPAP cell M3vwZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjo[ZFyUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjl6N{mg{txO MXjTRW5ITVJ?
human COLO-792 cell M{jyb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLBWHpKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{OUm3NkDPxE1? MlP2V2FPT0WU
human DU-145 cell M4LJU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnrTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMyQDh7IN88US=> NXnubpJGW0GQR1XS
NCI-H2122 cell NWLaT2hOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XsW2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkK4OUDPxE1? MX7TRW5ITVJ?
human SK-UT-1 cell M2G2bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXyxS2xoUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkm1NkDPxE1? MWjTRW5ITVJ?
LXF-289 cell MmHIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> M33mRXNCVkeHUh?=
human NCI-H1792 cell MkjTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzNyOU[g{txO M2rkbXNCVkeHUh?=
MCF7 cell NXPUTmxGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XJW2lvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|MzPzRizszN NIK5VnlUSU6JRWK=
HCT-15 cell MlTWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1HrO2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR|MjFOwG0> NEOxSlBUSU6JRWK=
human NCI-H358 cell NVPRT5h{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHVUnhXUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFM2QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{O1OVEh|ryP M4C1bXNCVkeHUh?=
human HLE cell NYXCWWhDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFWzWIZKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4PTJizszN NUe1bZZGW0GQR1XS
human SW1088 cell MmS0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moj4TY5pcWKrdHnvckBw\iCqdX3hckBUXzFyOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{Pzl5IN88US=> NVqwUVR4W0GQR1XS
human K5 cell M3jiS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkG0PUDPxE1? MYnTRW5ITVJ?
human SR cell MoPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfaW45KdmirYnn0bY9vKG:oIHj1cYFvKFOUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlU4OSEQvF2= NXLROFc2W0GQR1XS
human Calu-3 cell NXruUHRKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXuy[WdXUW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN4OEK1JO69VQ>? MY\TRW5ITVJ?
human SK-MEL-30 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\mcZlKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{m5NVMh|ryP MWTTRW5ITVJ?
human SW780 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVE1OiEQvF2= M1vpVXNCVkeHUh?=
NCI-H1563 cell NYTxcYQyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MonYTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzNEi0JO69VQ>? MXjTRW5ITVJ?
human MKN45 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLsSFZKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTl|MTFOwG0> M1fNNHNCVkeHUh?=
MDA-MB-157 cell NHe1SndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLYdoFlUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NlAyPSEQvF2= M322OHNCVkeHUh?=
human NCI-H522 cell MnjnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\ONHdSUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? NIXhT4ZUSU6JRWK=
human A2780 cell Ml7xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\acmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB|IN88US=> NGDtPWpUSU6JRWK=
human A498 cell NXL0W496T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4fESGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc3QTNizszN MYDTRW5ITVJ?
human BxPC-3 cell MoDJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrTfWJSUW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7M{[2JO69VQ>? M1zLbHNCVkeHUh?=
human A2058 cell M{TCeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVnnb2U3UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ6NESg{txO NFzuNVJUSU6JRWK=
human PC-14 cell MonSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYj3fnNOUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO NHj3XmhUSU6JRWK=
human KG-1 cell M3HNSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW1OFE6KM7:TR?= NU\U[lhWW0GQR1XS
human A375 cell NEnKc5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{n0fGlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVYyODNizszN MlG3V2FPT0WU
human SW1783 cell M4jYV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{TX[WlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> NFfsN3dUSU6JRWK=
human MKN1 cell MmTXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7kTY5pcWKrdHnvckBw\iCqdX3hckBOU05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64PFQyOiEQvF2= NUjo[GhQW0GQR1XS
NCI-H1650 cell M1TLXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh7MUdjhKDPxE1? NVyzeYl3W0GQR1XS
human HT-1376 cell M37CXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF|N{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlkzQTF6IN88US=> MlTVV2FPT0WU
SW872 cell MnXQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTGR2lqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTR2NUmg{txO NFHHeHdUSU6JRWK=
human RT-112 cell NEe3VVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrTSJJKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd2OEOg{txO M3jXbXNCVkeHUh?=
human HT-29 cell NYX1[4V4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1v6WGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4QTl4IN88US=> NVLjSlJiW0GQR1XS
human U-266 cell MoH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvVeHZKdmirYnn0bY9vKG:oIHj1cYFvKFVvMk[2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDNyMjFOwG0> M3z0U3NCVkeHUh?=
human HEL cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUi1NVch|ryP MmrHV2FPT0WU
human KU812 cell NXKxfnNDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xNVE3PCEQvF2= NY\mW3N[W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 300+ddH2O
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID